{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T21:51:46Z","timestamp":1769118706228,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100026893","name":"Center for Advancing Research Impact in Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100026893","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","award":["V3-24038"],"award-info":[{"award-number":["V3-24038"]}],"id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","award":["P5-0117"],"award-info":[{"award-number":["P5-0117"]}],"id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.eclinm.2025.103542","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:13:30Z","timestamp":1760660010000},"page":"103542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prevalence, determinants, and prognostic impact of polyvascular disease in patients hospitalised for atherosclerosis in Slovenia: a nationwide, retrospective cohort study"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2110-4581","authenticated-orcid":false,"given":"Kevin","family":"Pelicon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tja\u0161a","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinko","family":"Boc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalibor","family":"Gavri\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borut","family":"Jug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Do\u0161enovi\u0107 Bon\u010da","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103542_bib1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/eci.12222","article-title":"The impact of polyvascular disease on long-term outcome in percutaneous coronary intervention patients","volume":"44","author":"van der Meer","year":"2014","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.eclinm.2025.103542_bib2","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/eurheartj\/ehp355","article-title":"Three-year follow-up and event rates in the international REduction of Atherothrombosis for continued health registry","volume":"30","author":"Alberts","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eclinm.2025.103542_bib3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1161\/CIRCOUTCOMES.111.964379","article-title":"Polyvascular disease and long-term cardiovascular outcomes in older patients with non\u2013ST-Segment\u2013Elevation myocardial infarction","volume":"5","author":"Subherwal","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.eclinm.2025.103542_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.amjcard.2018.09.014","article-title":"Prevalence and outcomes of polyvascular (Coronary, Peripheral, or Cerebrovascular) disease in patients with diabetes mellitus (From the SAVOR-TIMI 53 Trial)","volume":"123","author":"Gutierrez","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.eclinm.2025.103542_bib5","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S2213-8587(18)30290-0","article-title":"Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial","volume":"6","author":"Bonaca","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eclinm.2025.103542_bib6","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1001\/archinte.164.19.2106","article-title":"Comparative benefits of clopidogrel and Aspirin in high-risk patient populations","volume":"164","author":"Hirsh","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.eclinm.2025.103542_bib7","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eclinm.2025.103542_bib8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/1358863X18775594","article-title":"Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: insights from the EUCLID trial","volume":"23","author":"Berger","year":"2018","journal-title":"Vasc Med"},{"key":"10.1016\/j.eclinm.2025.103542_bib9","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1161\/CIRCULATIONAHA.118.033898","article-title":"Effect of Liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and Polyvascular disease","volume":"137","author":"Verma","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.eclinm.2025.103542_bib10","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103542_bib11","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103542_bib12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijcard.2017.11.081","article-title":"Systematic detection of polyvascular disease combined with aggressive secondary prevention in patients presenting with severe coronary artery disease: the randomized America Study","volume":"254","author":"Collet","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.eclinm.2025.103542_bib13","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","article-title":"2024 ESC Guidelines for the management of peripheral arterial and aortic diseases","volume":"45","author":"Mazzolai","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eclinm.2025.103542_bib14","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1093\/eurheartj\/ehae466","article-title":"European society of cardiology: the 2023 atlas of cardiovascular disease statistics","volume":"45","author":"Timmis","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eclinm.2025.103542_bib15","author":"Bijec"},{"key":"10.1016\/j.eclinm.2025.103542_bib16","series-title":"R: a language and Environment for statistical Computing","year":"2019"},{"key":"10.1016\/j.eclinm.2025.103542_bib17","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/eurheartj\/ehp099","article-title":"Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes","volume":"30","author":"Bhatt","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eclinm.2025.103542_bib18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jacc.2020.05.048","article-title":"Atherosclerotic risk and statin use among patients with peripheral artery disease","volume":"76","author":"Colantonio","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eclinm.2025.103542_bib19","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.jacc.2007.11.077","article-title":"Long-term prognosis of patients with peripheral arterial disease","volume":"51","author":"Welten","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eclinm.2025.103542_bib20","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2006.03.067","article-title":"The influence of peripheral arterial disease on outcomes. A pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials","volume":"48","author":"Saw","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eclinm.2025.103542_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-2261-10-57","article-title":"The dynamics of mortality in follow-up time after an acute myocardial infarction, lower extremity arterial disease and ischemic stroke","volume":"10","author":"Vaartjes","year":"2010","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.eclinm.2025.103542_bib22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2261-5-14","article-title":"The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database","volume":"5","author":"Caro","year":"2005","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.eclinm.2025.103542_bib23","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1161\/CIRCULATIONAHA.124.068080","article-title":"Low-dose rivaroxaban plus aspirin in patients with peripheral artery disease undergoing lower extremity revascularization with and without concomitant coronary artery disease: insights from VOYAGER PAD","volume":"149","author":"Morrison","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.eclinm.2025.103542_bib24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2020.11.001","article-title":"Polyvascular disease: a narrative review of current evidence and a consideration of the role of antithrombotic therapy","volume":"315","author":"Weissler","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.eclinm.2025.103542_bib25","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s11886-024-02063-0","article-title":"Polyvascular disease: a narrative review of risk factors, clinical outcomes and treatment","volume":"26","author":"Tannu","year":"2024","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.eclinm.2025.103542_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.5239","article-title":"Polyvascular disease and risk of major adverse cardiovascular events in peripheral artery disease","volume":"1","author":"Gutierrez","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eclinm.2025.103542_bib27","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eclinm.2025.103542_bib28","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017948","article-title":"Meta-analysis of intensive lipid-lowering therapy in patients with polyvascular disease","volume":"10","author":"Alkhalil","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.eclinm.2025.103542_bib29","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.atherosclerosis.2011.08.024","volume":"219","author":"Hibi","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.eclinm.2025.103542_bib30","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jama.2010.1322","article-title":"Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with Atherothrombosis","volume":"304","author":"Bhatt","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2025.103542_bib31","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.clinthera.2023.09.020","article-title":"Global trends in atherosclerotic cardiovascular disease","volume":"45","author":"Nedkoff","year":"2023","journal-title":"Clin Ther"},{"key":"10.1016\/j.eclinm.2025.103542_bib32","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12890-023-02606-1","article-title":"Association between chronic obstructive pulmonary disease and cardiovascular disease in adults aged 40 years and above: data from NHANES 2013\u20132018","volume":"23","author":"Chen","year":"2023","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.eclinm.2025.103542_bib33","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.jacc.2009.05.073","article-title":"The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential?","volume":"54","author":"Messerli","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eclinm.2025.103542_bib34","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/eurheartj\/ehq328","article-title":"J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial","volume":"31","author":"Bangalore","year":"2010","journal-title":"Eur Heart J"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025004754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025004754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T05:30:25Z","timestamp":1769059825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025004754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":34,"alternative-id":["S2589537025004754"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103542","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence, determinants, and prognostic impact of polyvascular disease in patients hospitalised for atherosclerosis in Slovenia: a nationwide, retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103542","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103542"}}